Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study

OBJECTIVES: We investigated the efficacy and safety of pembrolizumab monotherapy as first-line treatment for poor Eastern Cooperative Oncology Group performance status (PS) and elderly patients with programmed cell death-ligand 1 (PD-L1)-positive advanced non-small cell lung cancer (NSCLC). We also...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiotsu, Shinsuke, Yoshimura, Akihiro, Yamada, Tadaaki, Morimoto, Kenji, Tsuchiya, Michiko, Yoshioka, Hiroshige, Hiranuma, Osamu, Chihara, Yusuke, Yamada, Takahiro, Hasegawa, Isao, Ohta, Takahiro, Takeda, Takayuki, Hiraoka, Noriya, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504658/
https://www.ncbi.nlm.nih.gov/pubmed/36158655
http://dx.doi.org/10.3389/fonc.2022.904644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504658/
https://www.ncbi.nlm.nih.gov/pubmed/36158655
http://dx.doi.org/10.3389/fonc.2022.904644

Ejemplares similares